Jiro Uehara

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

Youn H. Kim, M. Bagot, Lauren Pinter‐Brown et al. · The Lancet Oncology · 2018 · 645 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma

Naoya Yamazaki, Yoshio Kiyohara, Hisashi Uhara et al. · Cancer Science · 2017 · 126 citations · Full text

Medicine, Oncology, Pharmacology +17

Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients

Kaori Sakaizawa, Atsuko Ashida, Aya Uchiyama et al. · Journal of Dermatological Science · 2015 · 120 citations

Medicine, Molecular Genetics, Oncology +16

Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma

Yasuhiro Fujisawa, Shusuke Yoshikawa, Akane Minagawa et al. · Cancer Medicine · 2019 · 112 citations · Full text

Medicine, Dermatology, Oncology +17

Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase <scp>II</scp> study

Naoya Yamazaki, Yoshio Kiyohara, Hisashi Uhara et al. · Cancer Science · 2017 · 70 citations · Full text

Medicine, Immunology, Oncology +17